Previous Close | 32.40 |
Open | 33.00 |
Bid | 33.00 x 50000 |
Ask | 33.50 x 50000 |
Day's Range | 33.00 - 33.00 |
52 Week Range | 22.55 - 34.30 |
Volume | |
Avg. Volume | 184 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Jul 29, 2024 - Aug 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.